In a landmark decision for the field of cancer immunotherapy, the U.S. Food and Drug Administration (FDA) today approved a personalized cellular therapy developed by the University of Pennsylvania and Children’s Hospital of Philadelphia (CHOP) for the treatment of patients up to 25 years of age with B-cell precursor acute lymphoblastic leukemia (ALL) that is refractory or in second or later relapse.
Read the Department of Communications news release.
Press coverage:
New York Times
Washington Post
Wall Street Journal
The Guardian
Associated Press
Time
National Institutes of Health